---
title: "Berry Genomics released its performance for the first three quarters, with a net loss attributable to the parent company of 52.5637 million yuan"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263579292.md"
description: "According to the Zhitong Finance APP, Berry Genomics released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 686 million yuan, a year-on-year decrease of 16.65%. The net loss attributable to shareholders of the listed company was 52.5637 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 53.7914 million yuan"
datetime: "2025-10-30T16:44:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263579292.md)
  - [en](https://longbridge.com/en/news/263579292.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263579292.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263579292.md) | [繁體中文](https://longbridge.com/zh-HK/news/263579292.md)


# Berry Genomics released its performance for the first three quarters, with a net loss attributable to the parent company of 52.5637 million yuan

According to the Zhitong Finance APP, Berry Genomics (000710.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 686 million yuan, a year-on-year decrease of 16.65%. The net loss attributable to shareholders of the listed company was 52.5637 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 53.7914 million yuan

### 相关股票

- [Berry Genomics (000710.CN)](https://longbridge.com/zh-CN/quote/000710.CN.md)

## 相关资讯与研究

- [Jacobio Pharma: Differentiated Pan-KRAS Profile, Multiple Clinical Catalysts, and Solid Balance Sheet Underscore Buy Rating](https://longbridge.com/zh-CN/news/278909908.md)
- [11:41 ETNovafjord Expands Multi-Asset Trading Services With AI-Driven Arbitrage and Risk Management Tools](https://longbridge.com/zh-CN/news/278417992.md)
- [12:23 ETFull Circles Therapeutics Highlights Circular Single-Stranded DNA Platform Enabling Immune-Evasive Genome Writing in Nature Study](https://longbridge.com/zh-CN/news/278753990.md)
- [<![CDATA[FDA Approves Leucovorin Without a Clinical Trial for Cerebral Folate Transport Deficiency: Report ]]>](https://longbridge.com/zh-CN/news/278589943.md)
- [US FDA to expand leucovorin’s approved use, but not for autism, WaPo reports](https://longbridge.com/zh-CN/news/278524491.md)